olivLaw · US equity research
Beta Bionics, Inc. BBNX
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
Beta Bionics is a medical device company that develops the iLet Bionic Pancreas, which autonomously delivers insulin for people with type 1 diabetes. The company is reducing its reliance on one reimbursement channel by expanding the pharmacy benefit channel and preparing new indications, including type 2 diabetes. Its 2026 guidance points to revenue of roughly 131 to 136 million USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Beta Bionics, Inc. (BBNX) stock was 16.95 USD (+12.25% on the day), with market capitalisation 921.5 m USD, beta 1.71, 52-week range 8.86–31.99 USD. Latest reported quarter (Q3 2026): revenue of 35.5 m USD (+30.3% YoY), net income of -24.4 m USD, diluted EPS -0.52 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 45.3
- neutral
- Bollinger (20, 2)
- 14.84 – 20.62
- in the lower half of the band · %B 0.36 · band width 32.6%
- SMA 50 / 200
- 18.90 / 14.78
- mixed trend
- MACD (12, 26, 9)
- -0.57 / -0.33
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.6% | −1.1% | −9.5 pp | — |
| 3 months | +21.9% | −0.5% | +22.3 pp | — |
| 6 months | +60.4% | +4.4% | +56.0 pp | — |
| Year to date | −44.4% | +12.3% | −56.7 pp | — |
| 1 year | −39.1% | +13.5% | −52.6 pp | −29.7% |
| 3 years | unavailable | +76.4% | unavailable | −20.7% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20.4 m | 17.6 m | 23.2 m | 27.3 m | 32.1 m | 27.6 m | 32.0 m | 35.5 m |
| Cost of revenue | 8.8 m | 8.7 m | 10.7 m | 12.1 m | 13.2 m | 11.2 m | 13.1 m | 15.2 m |
| Gross profit | 11.7 m | 9.0 m | 12.5 m | 15.1 m | 18.9 m | 16.4 m | 18.9 m | 20.3 m |
| Research & development | 9.2 m | 7.6 m | 8.9 m | 8.2 m | 10.1 m | 10.4 m | 10.2 m | 12.0 m |
| Operating income | -13.0 m | -18.6 m | -19.9 m | -17.0 m | -16.1 m | -24.3 m | -25.6 m | -26.6 m |
| Net income | -18.1 m | -28.7 m | -16.9 m | -14.2 m | -13.5 m | -21.9 m | -23.4 m | -24.4 m |
| Diluted EPS | -2.72 ≈ | -0.93 | -0.39 | -0.33 | -0.30 ≈ | -0.49 | -0.53 | -0.52 |
| Operating cash flow | -14.3 m | -20.0 m | -13.6 m ≈ | -8.7 m ≈ | -8.6 m | -23.8 m | -14.6 m ≈ | -12.3 m ≈ |
| Capex | 561.0 k | 333.0 k | 1.8 m ≈ | 1.3 m ≈ | 1.9 m | 1.4 m | 1.0 m ≈ | 2.3 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 12.0 m | 65.1 m | 100.3 m |
| Revenue YoY | unavailable | +442.9% | +53.9% |
| Net income | -44.1 m | -54.8 m | -73.2 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -8.31 | -8.60 | -1.81 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -367.6% | -84.1% | -73.0% |
| Free cash flow | -32.8 m | -51.7 m | -56.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 31.6 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 287.6 m USD
- Total assets
- 328.7 m USD
- Debt / equity
- unavailable
- Current ratio
- 8.66x
- ROE
- unavailable
- ROA
- -30.6%
- FCF margin
- -56.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 12.0 m | 65.1 m | 100.3 m | SEC (XBRL)· 24 Feb 2026verified |
| Cost of revenue | 5.7 m | 29.2 m | 44.7 m | SEC (XBRL)· 24 Feb 2026verified |
| Gross profit | 6.3 m | 35.9 m | 55.5 m | SEC (XBRL)· 24 Feb 2026verified |
| Research & development | 17.9 m | 26.2 m | 34.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Operating income | -35.9 m | -45.3 m | -71.7 m | SEC (XBRL)· 24 Feb 2026verified |
| Income tax | — | 0 | 0 | SEC (XBRL)· 24 Feb 2026verified |
| Net income | -44.1 m | -54.8 m | -73.2 m | SEC (XBRL)· 24 Feb 2026verified |
| Diluted EPS | -8.31 | -8.60 | -1.81 | SEC (XBRL)· 24 Feb 2026verified |
| Weighted average diluted shares | 5.3 m | 6.4 m | 40.5 m | SEC (XBRL)· 24 Feb 2026verified |
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 26.6 m | 30.4 m | 31.6 m | SEC (XBRL)· 24 Feb 2026verified |
| Receivables | 4.4 m | 12.0 m | 17.1 m | SEC (XBRL)· 24 Feb 2026verified |
| Inventories | 1.2 m | 13.3 m | 21.7 m | SEC (XBRL)· 24 Feb 2026verified |
| Current assets | 103.6 m | 132.9 m | 267.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Property, plant & equipment, net | 2.5 m | 4.8 m | 8.6 m | SEC (XBRL)· 24 Feb 2026verified |
| Total assets | 110.0 m | 149.6 m | 328.7 m | SEC (XBRL)· 24 Feb 2026verified |
| Accounts payable | 1.2 m | 2.9 m | 5.0 m | SEC (XBRL)· 24 Feb 2026verified |
| Current liabilities | 10.6 m | 21.1 m | 30.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Total liabilities | 51.4 m | 73.6 m | 41.1 m | SEC (XBRL)· 24 Feb 2026verified |
| Equity | -203.1 m † | -245.4 m † | 287.6 m † | SEC (XBRL)· 24 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -32.4 m | -48.3 m | -50.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Capex | 402.0 k | 3.4 m | 5.3 m | SEC (XBRL)· 24 Feb 2026verified |
| Free cash flow | -32.8 m ≈ | -51.7 m ≈ | -56.2 m ≈ | SEC (XBRL)· 24 Feb 2026derived |
| Investing cash flow | -69.7 m | -3.5 m | -162.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Financing cash flow | 101.0 m | 55.6 m | 214.9 m | SEC (XBRL)· 24 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 921.5 m USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -65.3% | 18 (vs peers) | 33% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 8.9x | 100 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -7.2% | 0 (on a fixed band) | 44% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial18/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
BETA BIONICS, INC. (BBNX). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 100.3 m USD in 2025; YoY growth 53.9%; net margin -65.3%; ROE -23.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 8.9x
What contradicts it
- Net margin: -65.3%
- FCF yield: -7.2%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 129.3 bn | 36.2 | 16.0% | 13.8% | +11.2% | −8% / +15% |
| MMM3m Company | 100.2 bn | 28.9 | 80.8% | 14.0% | +1.5% | +13% / +134% |
| BSXBoston Scientific Corporation | 66.4 bn | 19.4 | 14.3% | 16.6% | +19.9% | −55% / −18% |
| BDXBecton, Dickinson And Company | 57.0 bn | 63.2 | 3.8% | 4.0% | +8.2% | +37% / +13% |
| RMDResMed Inc. | 33.8 bn | 21.9 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 33.0 bn | 34.8 | 37.7% | 19.4% | +15.6% | +39% / −23% |
| WSTWest Pharmaceutical Services, Inc. | 28.5 bn | 45.9 | 21.2% | 18.8% | +6.3% | +47% / +17% |
| SOLVSolventum Corporation | 15.2 bn | 10.9 | 34.0% | 17.3% | +0.9% | +5% / unavailable |
| GMEDGlobus Medical, Inc. | 11.7 bn | 22.3 | 11.8% | 17.0% | +16.7% | −4% / +94% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +31% / −34% |
| ICUIIcu Medical Inc | 4.3 bn | 144.2 | 1.4% | 1.4% | −6.3% | +16% / +97% |
| ATECAlphatec Holdings, Inc. | 1.3 bn | — | -1,888.0% | -10.3% | +25.0% | −63% / −30% |
| SIBNSi-Bone, Inc. | 1.1 bn | — | -7.7% | -6.2% | +20.2% | +28% / +32% |
| BBNXBeta Bionics, Inc. | 921.5 m | — | -23.9% | -65.3% | +53.9% | −39% / unavailable |
| KIDSOrthoPediatrics Corp | 875.0 m | — | -9.8% | -12.8% | +15.4% | +81% / +9% |
| SGHTSight Sciences, Inc. | 538.0 m | — | -50.1% | -32.1% | −3.1% | +16% / +184% |
| CERSCerus Corp | 487.7 m | — | -10.7% | -2.9% | +16.1% | +37% / +50% |
| SIShoulder Innovations, Inc. | 437.4 m | — | -151.9% | -58.3% | +49.6% | +36% / unavailable |
| OFIXOrthofix Medical Inc. | 395.9 m | — | -13.9% | -7.4% | +2.9% | −40% / −12% |
| CLPTClearPoint Neuro, Inc. | 325.7 m | — | -167.5% | -79.4% | +17.8% | −30% / +76% |
| TMCITreace Medical Concepts, Inc. | 292.7 m | — | -72.0% | -29.0% | +1.6% | +51% / −49% |
| CTSOCytosorbents Corporation | 286.6 m | — | -336.2% | -48.9% | +4.1% | −72% / −81% |
| OSUROrasure Technologies, Inc | 256.6 m | — | -14.1% | -43.7% | −38.1% | +56% / −49% |
| GUTSFractyl Health, Inc. | 154.8 m | — | — | — | −100.0% | −95% / unavailable |
| KRMDKoru Medical Systems, Inc. | 151.0 m | — | -10.5% | -4.0% | +22.2% | −45% / +45% |
1- and 3-year price returns: for BBNX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (27 Oct 2026 · results), 10-Q (27 Oct 2026).
In brief
Beta Bionics is a medical device company that develops the iLet Bionic Pancreas, which autonomously delivers insulin for people with type 1 diabetes. The company is reducing its reliance on one reimbursement channel by expanding the pharmacy benefit channel and preparing new indications, including type 2 diabetes 23. Its 2026 guidance points to revenue of roughly 131 to 136 million USD 3.
SWOT
Strengths
- The algorithm autonomously determines all insulin doses, which simplifies use compared with existing hybrid systems 1.
- Most new patients come from multiple daily injection therapy rather than competing pumps 23.
- Partnerships with glucose sensor providers allow integration with widely used platforms 1.
Weaknesses
Opportunities
Risks
- Limited commercial historymedium
The product was launched relatively recently, which makes it hard to evaluate future performance 1.
- Continuing operating losseshigh
The company cannot assure that it will achieve or sustain profitability in the future 1.
- Need for additional fundinghigh
Available funds could be sufficient only into the first half of 2028 if the rate of spending rises 13.
- Customer concentrationmedium
A small number of DME distributors account for a significant part of sales, and losing them could affect results 1.
- Dependence on third parties and regulatorsmedium
Relationships with sensor suppliers and FDA clearances for new products and indications could delay launches or reduce sales 13.
Investment thesis
What would need to be true (bull case)
- Sales growth in the second quarter of 2026 and rapid growth in the pharmacy channel could indicate the business model is scaling 3.
- If gross margin holds within the guided range, the company could gradually narrow its operating losses 3.
- Extension to type 2 diabetes and the Mint launch could open large markets if FDA clearances are obtained 13.
What would break the thesis
- Net and operating losses remain large relative to sales, and funding could become necessary earlier than estimated 13.
- Reliance on one product and a few distributors could amplify the effect of any sales or reimbursement shock 1.
- Larger competitors could respond with new products or more favorable commercial terms, limiting share gains 1.
What to watch
- Quarterly results and the PBP share of net salesQ3 2026
- Gross margin trend against the guided rangeQ3 2026
- FDA decision on the type 2 diabetes indicationmid-2027
- Commercial launch of Mint and any need for additional funding2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (27 Oct 2026 · results), 10-Q (27 Oct 2026).
The business
Beta Bionics, Inc. is a commercial-stage medical device company that designs and commercializes solutions for people with diabetes who require insulin, using advanced adaptive closed-loop algorithms 1. Its main product, the iLet Bionic Pancreas, was cleared by the FDA for type 1 diabetes in adults and children six and older and launched commercially in May 2023 in the United States 1. The installed base reached 35011 iLets as of December 31, 2025 1.
Segments
The iLet device and single-use products
The iLet combines a pump, algorithms that autonomously determine all insulin doses and a mobile app, while users buy cartridges and infusion sets separately as single-use products 1. All of the company's revenue comes from sales of these products 1.
DME and PBP reimbursement channels
The DME channel requires a large upfront payment, while the PBP channel involves a small upfront payment and more expensive consumables over time, which is why PBP is the company's strategic priority 12. PBP's share of net sales rose from 24 percent in 2025 to 37 percent in the first half of 2026 12.
Development: Mint and the bihormonal iLet
Mint is a tubeless patch pump in development, and the bihormonal iLet, which also delivers glucagon, is in clinical studies 13. The company has updated its expectation to fully commercialize Mint by the end of the second quarter of 2027, subject to FDA clearance 3.
Market context
The target market includes people with type 1 diabetes, estimated at about 1.9 million in the United States, all of whom require daily insulin 1. The company says only about one-third of people with type 1 diabetes use insulin pumps or hybrid systems, with the rest on multiple daily injections 2. Extending to type 2 diabetes requires a new FDA clearance, and a pivotal study started in July 2026 13.
Most of the company's new patients come from multiple daily injection therapy, suggesting the product attracts users who were not on pumps 23. Sales remain focused on endocrinology practices, with possible expansion to primary care physicians 12.
Trends
- Shift toward the pharmacy channelmixed
Expanding the PBP channel, with lower upfront payments, could speed adoption and reduce dependence on DME distributors 12. The negative initial gross margin on each device remains a near-term pressure 1.
- Improving gross margintailwind
Gross margin in the second quarter of 2026 rose compared with a year earlier, and the full-year margin guidance was raised at the lower end 3. Rapid PBP growth could still weigh on margins in some periods 1.
- Regulatory and reimbursement pressureheadwind
Changes in payor policies or healthcare reform could affect reimbursement and patient access 1. The company relies on CGM supplier agreements that may be terminated on relatively short notice 1.
Competitive position
Beta Bionics competes mainly with insulin pump makers such as Medtronic, Tandem and Insulet, which have greater market share, brand recognition, financial resources and distribution networks 1. Competition also comes from insulin pens, prefilled syringes, inhalable insulin and pharmaceutical companies 1.
The company says iLet has features its rivals' pumps do not, such as full autonomous dosing without carb counting and a pay-as-you-go reimbursement option 1. Insulet, however, offers a patch-form-factor product that iLet does not yet have 1.
- Medtronic
Insulin pump maker cited as a principal competitor, with greater resources and established provider relationships.
- Tandem
Insulin pump maker cited as a principal competitor, with well-established distribution networks.
- Insulet
Insulin pump maker offering a patch form factor, a category the Mint program aims to address.
- Insulin pen and syringe makers
Simpler alternatives to pumps cited as competitive pressure from outside the pump category.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report27 Oct 2026
- Current report27 Oct 2026Results of operations · Financial statements and exhibits
- Current report17 Sept 2026Other events · Financial statements and exhibits
- Current report15 Sept 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Quarterly report29 Jul 2026
- Current report29 Jul 2026Results of operations · Financial statements and exhibits
- Current report22 May 2026Shareholder vote
- Current report21 May 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Quarterly report21 Apr 2026
- Current report21 Apr 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Beta Bionics, Inc. · 24 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Beta Bionics, Inc. · 29 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Beta Bionics, Inc. · 29 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.